Depemokimab Versus Monthly Asthma Shots
Severe eosinophilic asthma often needs more than inhalers. Biologics that block type-2 inflammation can cut attacks. Most of those drugs still require an injection every two to eight weeks. Missed visits then become missed protection. Depemokimab is built to stretch that interval to twice a year.
The drug is an ultra-long-acting monoclonal antibody against interleukin-5. Engineers raised IL-5 binding affinity and changed the Fc region so the molecule stays in the body longer. Blood eosinophils stay suppressed across each 26-week dosing window. Brand names such as Exdensur have been approved in the United States, the United Kingdom, and the European Union as add-on maintenance therapy for eosinophilic or type-2 severe asthma in people aged 12 years and older. Some licences also cover severe chronic rhinosinusitis with nasal polyps.
Trial evidence comes mainly from SWIFT-1 and SWIFT-2. Pooled data showed about a 54 percent drop in annualised exacerbations versus placebo, both on top of standard inhaler care. Separate trial reports listed 58 percent and 48 percent reductions over 52 weeks. Effects appeared by week 4 and held through both dosing periods. Symptom and quality-of-life scores also improved in several analyses, especially in people with higher baseline symptom burden.
Older anti-IL-5 and related biologics already work. Mepolizumab, benralizumab, reslizumab, and others proved that targeting this pathway reduces attacks. Their weakness is logistics. Clinic calendars fill with monthly or eight-week appointments. Travel, work, and fear of injections erode persistence. Real-world series often show lower adherence than randomised trials. Each missed dose reopens a gap in eosinophil control.
Twice-yearly dosing attacks that gap.
Two supervised injections can replace six to twenty-six visits. Health systems may free infusion-chair time. Patients may stay on therapy longer simply because the schedule is easier. That is the adherence hypothesis. It is plausible. It is not yet proven at population scale.
The hypothesis has limits. A six-month gap also means a missed appointment costs half a year of coverage. Clinics must therefore track the next due date with more discipline, not less. People who need frequent review for comorbidities still come in. The biologic does not replace inhaler technique, trigger control, or oral-steroid stewardship.
Comparative data against active monthly biologics remain thinner than placebo-controlled results. Head-to-head adherence trials in routine Indian or other LMIC clinics have not defined whether two doses a year beat a familiar monthly nurse visit. Cost, cold chain, and specialist access will decide uptake as much as half-life. A high-priced ultra-long-acting shot that never reaches the district hospital cannot improve adherence there.
Patient selection still follows the eosinophilic, type-2 pathway.
Blood eosinophil count remains the practical biomarker in many centres. Comorbid nasal polyps and shorter asthma duration were linked with larger responses in post-hoc SWIFT analyses. Those signals need confirmation before they become rigid rules.
In short, depemokimab changes the calendar more than the target. IL-5 blockade is established. Biannual dosing is new. Whether fewer injections produce fewer attacks in real clinics depends on booking systems, price, and follow-up—not only on an extended half-life. Older monthly biologics remain the evidence base many teams already know how to deliver. The new option is worth using where the schedule itself is the barrier.